- Report
- August 2026
- 197 Pages
Global
From €3156EUR$3,545USD£2,712GBP
€3507EUR$3,939USD£3,014GBP
- Report
- August 2026
- 184 Pages
Global
From €3156EUR$3,545USD£2,712GBP
€3507EUR$3,939USD£3,014GBP
- Report
- April 2026
- 200 Pages
Global
From €2662EUR$2,990USD£2,288GBP
- Report
- April 2026
- 200 Pages
Global
From €2662EUR$2,990USD£2,288GBP
- Report
- June 2026
- 160 Pages
Global
From €5298EUR$5,950USD£4,552GBP
- Report
- May 2026
- 160 Pages
Global
From €5298EUR$5,950USD£4,552GBP
- Report
- March 2026
- 150 Pages
Global
From €5298EUR$5,950USD£4,552GBP
- Report
- March 2026
- 140 Pages
Global
From €5298EUR$5,950USD£4,552GBP
- Report
- August 2026
- 291 Pages
Global
From €2226EUR$2,500USD£1,913GBP
- Report
- September 2026
- 177 Pages
Global
From €5209EUR$5,850USD£4,476GBP
- Report
- August 2026
- 182 Pages
Global
From €3156EUR$3,545USD£2,712GBP
€3507EUR$3,939USD£3,014GBP
- Report
- August 2026
- 189 Pages
Global
From €3156EUR$3,545USD£2,712GBP
€3507EUR$3,939USD£3,014GBP
- Report
- August 2026
- 199 Pages
Global
From €3156EUR$3,545USD£2,712GBP
€3507EUR$3,939USD£3,014GBP
- Report
- August 2026
- 192 Pages
Global
From €3156EUR$3,545USD£2,712GBP
€3507EUR$3,939USD£3,014GBP
- Report
- August 2026
- 189 Pages
Global
From €3156EUR$3,545USD£2,712GBP
€3507EUR$3,939USD£3,014GBP
- Report
- August 2026
- 181 Pages
Global
From €3156EUR$3,545USD£2,712GBP
€3507EUR$3,939USD£3,014GBP
- Report
- August 2026
- 192 Pages
Global
From €3156EUR$3,545USD£2,712GBP
€3507EUR$3,939USD£3,014GBP
- Report
- August 2026
- 188 Pages
Global
From €3156EUR$3,545USD£2,712GBP
€3507EUR$3,939USD£3,014GBP
- Report
- August 2026
- 187 Pages
Global
From €3156EUR$3,545USD£2,712GBP
€3507EUR$3,939USD£3,014GBP
- Report
- August 2026
- 191 Pages
Global
From €3156EUR$3,545USD£2,712GBP
€3507EUR$3,939USD£3,014GBP

The Automated Insulin Delivery (AID) market is a subset of the larger diabetes devices market. AID systems are designed to help people with diabetes manage their condition by automatically delivering insulin to the body. These systems are typically composed of an insulin pump, a continuous glucose monitor (CGM), and a control algorithm. The CGM measures glucose levels in the body and sends the data to the control algorithm, which then calculates the amount of insulin needed and sends a signal to the insulin pump to deliver the appropriate dose.
AID systems are designed to provide more accurate and consistent insulin delivery than traditional methods, and can help reduce the risk of hypoglycemia and other diabetes-related complications. They are also designed to be user-friendly and provide users with more control over their diabetes management.
Some companies in the AID market include Medtronic, Insulet, Tandem Diabetes Care, Bigfoot Biomedical, and Senseonics. Show Less Read more